Skip to main content
padlock icon - secure page this page is secure

Technetium-99m Cysteine; A Novel Radiopharmaceutical for Detection of Experimental Myocardial Infarction in Rats

Buy Article:

$68.00 + tax (Refund Policy)

Infarct avid radiopharmaceuticals are necessary for rapid and timely diagnosis of acute myocardial infarction. None of the infarct avid radiopharmaceuticals so far developed fulfill all the required criteria like rapid localization at the infarct, high avidity and specificity, and reasonable duration of scan positivity. 99mTc Cysteine was already reported from this laboratory as a suitable radiopharmaceutical to determine both morphology and function of kidney. The chemical structure of this radiopharmaceutical was also established. The present study demonstrates the affinity of the same chelate for damaged myocardial mass. 99mTc-cysteine was first tested on isoproterenol induced damaged rat myocardium, when ECG and histological studies demonstrated significant damage of the heart muscle following isoproterenol injection. The results were compared to that of 99mTc-glucarate. The uptake of 99mTc-cysteine in damaged rat myocardium was maximum (0.45% ID/g) when the animals were treated with isoproterenol 18 hrs before radiopharmaceutical injection; under the same experimental protocol 99mTc glucarate exhibited maximum heart uptake (0.263% ID/g) when injected 8 hrs after isoproterenol treatment. Evaluation was also performed on rat models of reperfused and non reperfused acute myocardial infarction. Animals were sacrificed after radiopharmaceutical injection and the excised hearts were subjected to radionuclide imaging, TTC and H-E staining. 99mTc-Cysteine chelate localized predominantly in the damaged portion. The highest infarct/viable tissue activity ratio (12/1) was obtained in 90 min occlusion model (protocol-2).





No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: 99m Tc glucaric acid; 99m Tc-pyrophosphate; 99mTc cysteine; 99msulfhydryl (-SH) moiety; DL-isoproterenol hydrochloride; ECG changes; Electrocardiography; H-E staining; Hematoxylin - Eosin Staining; L- cystine; Myocardial Infarction; NaI well counter; PE-50 polyethylene; Postmortem Myocardial Study; Radiochemical Purity Analysis; Radiopharmaceutical; TTC Staining; Tc-L-cysteine; Tc-cysteine; Technetium-99m; Technetium-99m Cysteine; Technetium-99m-cysteine; X-ray crystallographic method; cardiac muscle fibre; coronary artery disease; fibroblastic proliferation; focal haemorrhage; hyperaemia; iron ascorbate reduction method; isoproterenol; isostructural oxorhenium; lymphocytic exudation; myocardial damage; myometrium; oxotechnetium(Tc)-L cysteinate; polymorphonu clear leukocytes; polymorphonuclear leukocytes; radiolabeled antimyosin antibody; rhenium cysteine chelate; scintigraphic detection; scintillation counter; tetrabutyl ammonium chloride; thiopentone sodium anaesthesia

Document Type: Research Article

Publication date: October 1, 2010

More about this publication?
  • Current Radiopharmaceuticals publishes original research articles, letters, reviews, drug clinical trial studies and guest edited issues on all aspects of research and development of radiolabelled compound preparations. The scope of the journal covers the following areas: radio imaging techniques, therapies; preparation and application of radionuclide compounds including the incorporation of tracer methods used in scientific research and applications.
  • Editorial Board
  • Information for Authors
  • Subscribe to this Title
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more